18 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion http://www.zacks.com/stock/news/421467/biotech-stock-roundup-amgns-nuevolution-buyout-celg-incy-drugs-label-expansion?cid=CS-ZC-FT-421467 May 29, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Why Cancer-Fighting Stocks & ETFs Are Soaring http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108 Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Company News For Jun 4, 2019 http://www.zacks.com/stock/news/424463/company-news-for-jun-4-2019?cid=CS-ZC--424463 Jun 04, 2019 - Companies In The News Are: EE,CY,AMGN,MRK
Was ASCO Quieter for Big Drug/Biotech Stocks This Year? http://www.zacks.com/stock/news/425444/was-asco-quieter-for-big-drug-biotech-stocks-this-year?cid=CS-ZC-FT-425444 Jun 06, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Roche Receives FTC Request for Further Data on Spark Buyout http://www.zacks.com/stock/news/427145/roche-receives-ftc-request-for-further-data-on-spark-buyout?cid=CS-ZC-FT-427145 Jun 10, 2019 - Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/428338/mercks-keytruda-wins-fda-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-428338 Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris http://www.zacks.com/stock/news/429338/roche-reports-positive-data-on-rituxan-for-pemphigus-vulgaris?cid=CS-ZC-FT-429338 Jun 13, 2019 - Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti http://www.zacks.com/stock/news/429548/amgen-allergan-get-fda-nod-for-herceptin-biosimilar-kanjinti?cid=CS-ZC-FT-429548 Jun 14, 2019 - FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal https://www.fool.com/investing/2019/06/18/3-big-drugmakers-most-likely-to-make-acquisitions.aspx?source=iedfolrf0000001 Jun 18, 2019 - Pfizer could be only the first of several to spend billions buying smaller biotech.
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data http://www.zacks.com/stock/news/431676/biotech-stock-roundup-amgen-gets-fda-nod-for-kanjinti-regeneron-presents-data?cid=CS-ZC-FT-431676 Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Pages: 12

Page 1